Xarelto success in paediatric venous thromboembolism
The full findings of the study were presented during a late-breaking session at the 27th Congress of the International Society on Thrombosis and Haemostasis.
Read More
Tag: rivaroxaban
Bayer, J&J’s Xarelto fails to hit PhIII targets
Bayer and Johnson & Johnson’s plans to expand the scope of blood thinner Xarelto have hit a setback after the drug failed to hit targets in two studies in venous thromboembolism and heart failure studies.
Read More
Bayer, Janssen’s Xarelto cuts risk of amputation, death
Two new analyses of data from the COMPASS trial show that Bayer and Janssen’s blood thinner Xarelto significant cut the amputation rate for patients with peripheral artery disease and also a 23 percent reduction in deaths in patients with coronary artery disease.
Read More
Bayer files low-dose Xarelto/aspirin combo
Bayer is seeking permission to market in Europe its bloodthinner Xarelto in combination with aspirin to reduce the risk of cardiovascular events in patients with coronary or peripheral artery disease.
Read More
EU OKs low-dose Xarelto to prevent recurrent VTE
A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.
Read More
Bayer’s Xarelto beats aspirin in preventing blood clots
Data from a late-stage trial show that Bayer and Janssen’s Xarelto was better than aspirin at protecting patients from recurrent venous thromboembolism.
Read More
Bayer/Janssen’s Xarelto artery disease trial stopped early
Bayer/Janssen’s bloodthinner Xarelto has shown clear efficacy in preventing major cardiovascular events (MACE) in patients with coronary or peripheral artery disease taking part in the COMPASS trial, prompting an early halt to the late-stage study.
Read More
EU to review Portola’s blood-thinner antidote
The group is seeking conditional approval for the drug’s use when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding and for patients requiring urgent or emergency surgery.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
